Development of diagnostic antibodies against immunoglobulin heavy chain variable region for heavy chain amyloidosis (AH amyloidosis).

AH amyloidosis diagnostic antibody immunoglobulin heavy chain immunohistochemistry variable region

Journal

Pathology international
ISSN: 1440-1827
Titre abrégé: Pathol Int
Pays: Australia
ID NLM: 9431380

Informations de publication

Date de publication:
Apr 2021
Historique:
received: 05 12 2020
accepted: 27 01 2021
pubmed: 14 3 2021
medline: 19 1 2022
entrez: 13 3 2021
Statut: ppublish

Résumé

It is difficult to diagnose immunoglobulin heavy chain amyloidosis (AH amyloidosis) without proteomic analysis due to no useful diagnostic antibodies. The aim of this study was to develop diagnostic antibodies available to immunohistochemistry and immunoblotting. Two rabbit anti-heavy chain variable region antibodies were generated and evaluated in immunohistochemical studies performed on 11 AH amyloidosis patients and 64 patients with other systemic amyloidoses. Additionally, immunoblotting was performed using extracted amyloid protein from one patient and serum samples from two patients with AH amyloidosis. Immunohistochemical analysis generated a positive outcome in 10 of 11 AH amyloidosis patients (sensitivity 90.9%). While positive staining was also observed in 9 of 64 non-AH amyloidosis patients (specificity 85.9%), substitution of the blocking agent reversed the positive reactivity in 5 of 9 patients. Amyloid protein band was clearly detected via immunoblotting analysis, and protein bands with similar molecular weights of amyloid protein were observed in serum samples from patients with AH amyloidosis. The two antibodies may represent a powerful diagnostic tool for AH amyloidosis. In addition, our data revealed the existence of amyloidogenic variable region fragments in the serum of patients, suggesting their potential as diagnostic markers for AH amyloidosis.

Identifiants

pubmed: 33713540
doi: 10.1111/pin.13081
doi:

Substances chimiques

Antibodies 0
Immunoglobulin Heavy Chains 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

245-254

Subventions

Organisme : Ministry of Education, Culture, Sports, Science and Technology (Japan)
ID : KAKENHI: 17K08739
Organisme : Amyloid Research Committee, Intractable Disease Division, Ministry of Health, Labor and Welfare in Japan

Informations de copyright

© 2021 Japanese Society of Pathology and John Wiley & Sons Australia, Ltd.

Références

Benson MD, Buxbaum JN, Eisenberg DS et al. Amyloid nomenclature 2018: Recommendations by the International Society of Amyloidosis (ISA)nomenclature committee. Amyloid 2018; 25: 215-19.
Kyle RA, Gertz MA. Primary systemic amyloidosis: Clinical and laboratory features in 474 cases. Semin Hematol 1995; 32: 45-59.
Eulitz M, Weiss DT, Solomon A. Immunoglobulin heavy chain-associated amyloidosis. Proc Natl Acad Sci USA 1990; 87: 6542-46.
Solomon A, Weiss DT, Murphy C. Primary amyloidosis associated with a novel heavy-chain fragment (AH amyloidosis). Am J Hematol 1994; 45: 171-76.
Nasr SH, Lobritto SJ, Lauring BP, Arend LJ, D'Agati VD, Markowitz GS. A rare complication of monoclonal gammopathy. Am J Kidney Dis 2002; 40: 867-71.
Mai HL, Sheikh-Hamad D, Herrera GA, Gu X, Truong LD. Immunoglobulin heavy chain can be amyloidogenic: Morphologic characterization including immunoelectron microscopy. Am J Surg Pathol 2003; 27: 541-45.
Copeland JN, Kouides PA, Grieff M, Nadasdy T. Metachronous development of nonamyloidogenic [lambda] light chain deposition disease and IgG heavy chain amyloidosis in the same patient. Am J Surg Pathol 2003; 27: 1477-82.
Yazaki M, Fushimi T, Tokuda T et al. A patient with severe renal amyloidosis associated with an immunoglobulin gamma heavy chain fragment. Am J Kidney Dis 2004; 43: e23-28.
Gono T, Yazaki M, Fushimi T et al. AH amyloidosis associated with lymphoplasmacytic lymphoma secreting a monoclonal gamma heavy chain carrying an unusual truncated D segment. Am J Kidney Dis 2006; 47: 908-14.
Miyazaki D, Yazaki M, Gono T et al. AH amyloidosis associated with an immunoglobulin heavy chain variable region (VH1) fragment: A case report. Amyloid 2008; 15: 125-28.
Sethi S, Theis JD, Leung N et al. Mass spectrometry-based proteomic diagnosis of renal immunoglobulin heavy chain amyloidosis. Clin J Am Soc Nephrol 2010; 5: 2180-87.
Pradhan MA, Henderson RA, Patel D, McGhee CNJ, Vincent AL. Heavy-chain amyloidosis in TGFBI-negative and gelsolin-negative atypical lattice corneal dystrophy. Cornea 2011; 30: 1163-66.
Nasr SH, Said SM, Valeri AM et al. The diagnosis and characteristics of renal heavy-chain and heavy/light-chain amyloidosis and their comparison with renal light-chain amyloidosis. Kidney Int 2013; 83: 463-70.
Manabe S, Hatano M, Yazaki M, Nitta K, Nagata M. Renal AH amyloidosis associated with a truncated immunoglobulin heavy chain undetectable by immunostaining. Am J Kid Dis 2015; 66: 1095-100.
Hassoun Y, Kharfan-Dabaja MA, Baz R. Bortezomib plus dexamethasone results in a late organ response in primary heavy-chain amyloidosis without a hematologic response. Hematol Oncol Stem Cell Ther 2015; 8: 138-39.
Wu HT, Wen YB, Ye W et al. Underlying IgM heavy chain amyloidosis in treatment-refractory IgA nephropathy: A case report. World J Clin Case 2019; 7: 3055-61.
Otaka Y, Goda F, Nakazato Y, Tsutsui T. Systemic heavy- and light chain-amyloidosis presenting nephrotic syndrome and congestive heart failure: A case presentation and literature review. Amyloid 2019; 26: 95-96.
Abe R, Katoh N, Takahashi Y et al. Distribution of amyloidosis subtypes based on tissue biopsy site- consecutive analysis of 729 patients at a single amyloidosis center in Japan. Pathol Int, 71. 70-79. https://doi.org/10.1111/pin.13041
Ichimata S, Kobayashi M, Shimojo H, Katoh N, Yazaki M, Kanno H. Usefulness of gastroduodenal biopsy in the differential diagnosis of systemic AH amyloidosis from systemic AL amyloidosis. Histopathology 2018; 73: 230-39.
Kim WS, Nishizawa T, Yoshimizu M. Non-specific adsorption of fish immunoglobulin M (IgM) to blocking reagents on ELISA plate wells. Dis Aquat Organ 2007; 78: 55-59.
Bergström J, Murphy CL, Weiss DT et al. Two different types of amyloid deposits-apolipoprotein A-IV and transthyretin-in a patient with systemic amyloidosis. Lab Invest 2004; 84: 981-88.
Mahmood S, Gilbertson JA, Rendell N et al. Two types of amyloid in a single heart. Blood 2014; 124: 3025-27.
Tan SY, Murdoch IE, Sullivan TJ et al. Primary localized orbital amyloidosis composed of the immunoglobulin gamma heavy chain CH3 domain. Clin Sci 1994; 87: 487-91.
Solomon A, Frangione B, Franklin EC. Bence Jones proteins and light chains of immunoglobulins. Preferential association of the V lambda VI subgroup of human light chains with amyloidosis AL (lambda). J Clin Invest 1982; 70: 453-56.

Auteurs

Mayuko Nakagawa (M)

Institute for Biomedical Sciences, Shinshu University, Nagano, Japan.
Clinical Laboratory Sciences Division, Shinshu University Graduate School of Medicine, Nagano, Japan.

Masahide Yazaki (M)

Institute for Biomedical Sciences, Shinshu University, Nagano, Japan.
Clinical Laboratory Sciences Division, Shinshu University Graduate School of Medicine, Nagano, Japan.

Fuyuki Kametani (F)

Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.

Nagaaki Katoh (N)

Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Nagano, Japan.

Tsuneaki Yoshinaga (T)

Institute for Biomedical Sciences, Shinshu University, Nagano, Japan.
Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Nagano, Japan.

Keiichi Higuchi (K)

Institute for Biomedical Sciences, Shinshu University, Nagano, Japan.
Department of Aging Biology, Shinshu University School of Medicine, Nagano, Japan.

Yoshiki Sekijima (Y)

Institute for Biomedical Sciences, Shinshu University, Nagano, Japan.
Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Nagano, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH